KOLEK, Vítězslav, Pavel ZATLOUKAL, Miloš PEŠEK, František SALAJKA, Jana SKŘIČKOVÁ, Dimka SIXTOVÁ, Luboš PETRUŽELKA, Ivona GRYGÁRKOVÁ, Leona KOUBKOVÁ a Michal ŠTÍCHA. Pemetrexed in the firs line chemotherapy of malignant pleuralmesotelioma. A multicentre prospective study. In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. 2011. ISSN 1556-0864. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{946762, author = {Kolek, Vítězslav and Zatloukal, Pavel and Pešek, Miloš and Salajka, František and Skřičková, Jana and Sixtová, Dimka and Petruželka, Luboš and Grygárková, Ivona and Koubková, Leona and Štícha, Michal}, booktitle = {Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer}, keywords = {malignant pleural mesotelioma; Pemetrexed; first line chemotherapy survival}, language = {eng}, title = {Pemetrexed in the firs line chemotherapy of malignant pleuralmesotelioma. A multicentre prospective study}, year = {2011} }
TY - CONF ID - 946762 AU - Kolek, Vítězslav - Zatloukal, Pavel - Pešek, Miloš - Salajka, František - Skřičková, Jana - Sixtová, Dimka - Petruželka, Luboš - Grygárková, Ivona - Koubková, Leona - Štícha, Michal PY - 2011 TI - Pemetrexed in the firs line chemotherapy of malignant pleuralmesotelioma. A multicentre prospective study KW - malignant pleural mesotelioma KW - Pemetrexed KW - first line chemotherapy survival N2 - Malignant pleural mesothelioma (MPM) is a tumour with extremely unfavourable prognosis. Early diagnostic is rarely possible and chemotherapy has only a limited value in prolongation of survival. During the last years pemetrexed became the standard 1st line chemotherapy. ER -
KOLEK, Vítězslav, Pavel ZATLOUKAL, Miloš PEŠEK, František SALAJKA, Jana SKŘIČKOVÁ, Dimka SIXTOVÁ, Luboš PETRUŽELKA, Ivona GRYGÁRKOVÁ, Leona KOUBKOVÁ a Michal ŠTÍCHA. Pemetrexed in the firs line chemotherapy of malignant pleuralmesotelioma. A multicentre prospective study. In \textit{Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer}. 2011. ISSN~1556-0864.
|